Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab

We report here a taxol–bevacizumab-responsive metastatic melanoma case. Although the patient had been heavily pretreated for two years, she did not show any stabilisation or objective response of her disease. After treatment with taxol and bevacizumab combination an impressive response was obtained.